5 Results for "

mutation-selective

" in MedChemExpress (MCE) Product Catalog:
Products (5)

5 Results for "mutation-selective" in MCE Product Catalog:

63
63 Cited Publications
Cat. No.: HY-130149
CAS No.: 2326521-71-3
Purity:  99.81%
Synonyms: MRTX849
Target:  

Ras

Research Areas:  

Cancer

Adagrasib (MRTX849) is a potent, orally-available, and mutation-selective covalent inhibitor of KRAS G12C with potential antineoplastic activity. Adagrasib covalently binds to KRAS G12C at the cysteine at residue 12, locks the protein in its inactive GDP-bound conformation, and inhibits KRAS-dependent signal transduction .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-112299
CAS No.: 1661854-97-2
Purity:  99.81%
Synonyms: TAS6417; CLN-081
Target:  

EGFR Apoptosis

Research Areas:  

Cancer

Zipalertinib (TAS6417; CLN-081) is a highly effective, orally active and pan-mutation-selective EGFR tyrosine kinase inhibitor with a unique scaffold fitting into the ATP-binding site of the EGFR hinge region, with IC50 values ranging from 1.1-8.0 nM .
loading...
    loading...
Cat. No.: HY-137516A
CAS No.: 2502156-12-7
Target:  

PROTACs Ras

Research Areas:  

Cancer

LC-2 epimer is a differential isomer of LC-2. LC-2 is a mutation-selective PROTAC depressant for KRAS and contains a ligand for the von Hippel Lindau E3 ligase linked to the KRAS inhibitor MRTX849 .
loading...
    loading...
Cat. No.: HY-156167
CAS No.: 2704562-80-9
Target:  

LRRK2

Research Areas:  

Neurological Disease

LRRK2-IN-10 (compound 34) is a potent, mutation-selective, and brain penetrant G2019S-LRRK2 kinase inhibitor with IC50s of 11 nM and 5.2 nM for G2019S-LRRK2 pS935 and G2019S-LRRK2 pS1292, respectively. LRRK2-IN-10 has the potential for Parkinson's disease research .
loading...
    loading...
Cat. No.: HY-182044
Target:  

Ras Apoptosis PARP Caspase CDK

Research Areas:  

Cancer

MRTX849-amide-C4-(o)-carborane is a KRAS G12C inhibitor with mutation selectivity for cells expressing KRAS G12C. MRTX849-amide-C4-(o)-carborane shows low intrinsic cytotoxicity in cancer cells. MRTX849-amide-C4-(o)-carborane covalently binds to Cys12 of KRAS G12C, recruits Hsp70, promotes ubiquitination, and induces proteasome-dependent degradation of the target protein. MRTX849-amide-C4-(o)-carborane inhibits the activity of the downstream ERK signaling pathway and induces apoptosis signaling in cancer cells. MRTX849-amide-C4-(o)-carborane is applicable for the research of KRAS G12C-positive cancers .
loading...
    loading...